EA200601120A1 - N-arylpiperidine-substituted biphenylcarboxamides as apolipoprotein b - Google Patents
N-arylpiperidine-substituted biphenylcarboxamides as apolipoprotein bInfo
- Publication number
- EA200601120A1 EA200601120A1 EA200601120A EA200601120A EA200601120A1 EA 200601120 A1 EA200601120 A1 EA 200601120A1 EA 200601120 A EA200601120 A EA 200601120A EA 200601120 A EA200601120 A EA 200601120A EA 200601120 A1 EA200601120 A1 EA 200601120A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- arylpiperidine
- apolipoprotein
- biphenylcarboxamides
- substituted biphenylcarboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
N-aryl piperidine substituted biphenylcarboxamides compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03104601 | 2003-12-09 | ||
PCT/EP2004/053280 WO2005058824A2 (en) | 2003-12-09 | 2004-12-06 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200601120A1 true EA200601120A1 (en) | 2006-10-27 |
EA009081B1 EA009081B1 (en) | 2007-10-26 |
Family
ID=34684566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200601120A EA009081B1 (en) | 2003-12-09 | 2004-12-06 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
Country Status (19)
Country | Link |
---|---|
US (1) | US8772494B2 (en) |
EP (1) | EP1694644B1 (en) |
JP (1) | JP4790626B2 (en) |
KR (1) | KR101125120B1 (en) |
CN (1) | CN100548985C (en) |
AT (1) | ATE548350T1 (en) |
AU (1) | AU2004299295B2 (en) |
BR (1) | BRPI0417469B8 (en) |
CA (1) | CA2547243C (en) |
EA (1) | EA009081B1 (en) |
ES (1) | ES2383179T3 (en) |
HK (1) | HK1100559A1 (en) |
IL (1) | IL176171A (en) |
NO (1) | NO337251B1 (en) |
NZ (1) | NZ546964A (en) |
SG (1) | SG149001A1 (en) |
UA (1) | UA83510C2 (en) |
WO (1) | WO2005058824A2 (en) |
ZA (1) | ZA200604718B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053436A1 (en) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
EP3431602A1 (en) | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
JP5814505B2 (en) | 2006-04-03 | 2015-11-17 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising antimiRNA antisense oligonucleotide |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
DK2149605T3 (en) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Short RNA antagonist compounds to modulate the desired mRNA |
AU2008228243B2 (en) | 2007-03-22 | 2014-05-15 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
ES2541442T3 (en) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | MicroRNA-mediated modulation of colony stimulating factors |
WO2010122538A1 (en) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
CN112263682A (en) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | Antisense oligomers and conjugates targeting PCSK9 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Polyarylcarboxamides useful as lipid lowering agents |
JO2390B1 (en) * | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Lipid lowering biphenulcarboxamides |
GB0109287D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
-
2004
- 2004-06-12 UA UAA200605783A patent/UA83510C2/en unknown
- 2004-12-06 EA EA200601120A patent/EA009081B1/en not_active IP Right Cessation
- 2004-12-06 SG SG200809026-8A patent/SG149001A1/en unknown
- 2004-12-06 CA CA2547243A patent/CA2547243C/en not_active Expired - Fee Related
- 2004-12-06 AT AT04804685T patent/ATE548350T1/en active
- 2004-12-06 NZ NZ546964A patent/NZ546964A/en not_active IP Right Cessation
- 2004-12-06 JP JP2006543538A patent/JP4790626B2/en not_active Expired - Fee Related
- 2004-12-06 CN CNB2004800362613A patent/CN100548985C/en not_active Expired - Fee Related
- 2004-12-06 BR BRPI0417469A patent/BRPI0417469B8/en not_active IP Right Cessation
- 2004-12-06 US US10/580,530 patent/US8772494B2/en not_active Expired - Fee Related
- 2004-12-06 KR KR1020067013049A patent/KR101125120B1/en active IP Right Grant
- 2004-12-06 EP EP04804685A patent/EP1694644B1/en active Active
- 2004-12-06 WO PCT/EP2004/053280 patent/WO2005058824A2/en active Application Filing
- 2004-12-06 AU AU2004299295A patent/AU2004299295B2/en not_active Ceased
- 2004-12-06 ES ES04804685T patent/ES2383179T3/en active Active
-
2006
- 2006-06-07 IL IL176171A patent/IL176171A/en active IP Right Grant
- 2006-06-08 ZA ZA200604718A patent/ZA200604718B/en unknown
- 2006-07-04 NO NO20063103A patent/NO337251B1/en not_active IP Right Cessation
-
2007
- 2007-05-30 HK HK07105744.1A patent/HK1100559A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ546964A (en) | 2009-03-31 |
KR101125120B1 (en) | 2012-03-21 |
EP1694644B1 (en) | 2012-03-07 |
BRPI0417469B8 (en) | 2021-05-25 |
JP2007513921A (en) | 2007-05-31 |
AU2004299295A1 (en) | 2005-06-30 |
WO2005058824A3 (en) | 2005-10-27 |
ES2383179T3 (en) | 2012-06-18 |
SG149001A1 (en) | 2009-01-29 |
JP4790626B2 (en) | 2011-10-12 |
NO20063103L (en) | 2006-09-05 |
AU2004299295B2 (en) | 2010-07-15 |
HK1100559A1 (en) | 2007-09-21 |
CA2547243C (en) | 2012-10-23 |
EP1694644A2 (en) | 2006-08-30 |
ZA200604718B (en) | 2007-10-31 |
UA83510C2 (en) | 2008-07-25 |
IL176171A (en) | 2013-08-29 |
BRPI0417469B1 (en) | 2019-06-25 |
EA009081B1 (en) | 2007-10-26 |
KR20060111628A (en) | 2006-10-27 |
IL176171A0 (en) | 2006-10-05 |
CN100548985C (en) | 2009-10-14 |
CA2547243A1 (en) | 2005-06-30 |
US20070099934A1 (en) | 2007-05-03 |
US8772494B2 (en) | 2014-07-08 |
ATE548350T1 (en) | 2012-03-15 |
CN1890217A (en) | 2007-01-03 |
NO337251B1 (en) | 2016-02-22 |
WO2005058824A2 (en) | 2005-06-30 |
BRPI0417469A (en) | 2007-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100559A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
HRP20050103B1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
EA200601660A1 (en) | MTP INHIBITING ARYLIPIPERIDINES OR PIPERASINES FURNISHED WITH 5-MEMBER HETEROCYCLES | |
SE0200920D0 (en) | Novel compounds | |
ATE419848T1 (en) | CYCLOALKYL-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1 | |
NO20070224L (en) | 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof | |
ATE442349T1 (en) | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | |
SE0301700D0 (en) | Novel compounds | |
DE60315336D1 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV (DPP-IV) | |
SE0300480D0 (en) | Novel compounds | |
SE0401762D0 (en) | Novel compounds | |
SE0302139D0 (en) | Novel compounds | |
DE602004008959D1 (en) | BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE | |
JO2390B1 (en) | Lipid lowering biphenulcarboxamides | |
SE0401970D0 (en) | Novel compounds | |
JO2409B1 (en) | Biphenylcarboxamides useful as lipid lowering agents | |
ATE412636T1 (en) | PIPERAZINYLPYRIDINE DERIVATIVES AS AN AGAINST OBESITY | |
SE0402925D0 (en) | Novel Compounds | |
NO20060718L (en) | Substituted thiophones and their use | |
DE602004031410D1 (en) | INDIVIDUAL DERIVATIVES AS PHARMACEUTICALS | |
SE0401763D0 (en) | Compounds | |
SE0303280D0 (en) | Novel compounds | |
EA200870223A1 (en) | DERIVATIVES OF BENZOIZOINDOL FOR THE TREATMENT OF PAIN | |
NO20063790L (en) | Substituted azetidine compositions as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | |
ATE308513T1 (en) | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |